top of page
News
CureTrust Shares Imperative to Optimize Reimbursement and Access for Breakthrough Therapies at NORD
On a panel with biotech luminaries at NORD (National Organization for Rare Disorders), David Tischler, CureTrust CEO, illustrates why innovative specialty and rare disease medicines pose a challenge for employer-based insurers and what we can do to help more patients access treatment without breaking the system.
bottom of page